Kevin, thanks for addressing this issue. It's a very important one since The Street has made a huge negative out of the conversion of this debt. Hopefully we'll see a PR at the end of the day after trading closes.
Why would anyone pay 24% to borrow my Mannkind shares?
Kevin Sayer is the CEO of Dexcom. You can take what he says to the bank because his company sells products that monitor glucose for diabetics on a continuous basis. Thank you itellthefuture777 for finding this.
Kevin Sayer, DexCom, Inc. $6 billion company that does continuous glucose monitoring.
"Many of the Afrezza patients are CGM users and they're Twitter fanatics. They take pictures of their CGM lines because they're flat, because Afrezza works so quickly that they no longer eat a meal and have this big spike in glucose that goes on for a while before the insulin finally kicks in and then takes them way down because the tail lasts so long. They're in heaven. Now I don't know what that means for Afrezza sales, but there is a group of people who absolutely love it and use our product and have very good results."
I guess you're one of the shorts. You know that a lawsuit against Mannkind would kill the stock price and seriously damage the company, right?
Here's what Nate said about the GS conference: "Having just finished listening to MannKind’s presentation at the Goldman Sachs Global Healthcare Conference, I can tell you that I am more confident than ever that we are sitting on what I believe will eventually become a huge winner for us in our portfolio."
The CEO was very positive in his presentations. They have clinical activity in major cancers (HCC and prostate). The stock was $3.00/share a year ago without these new positive results.
I've noticed much higher egg prices for a dozen large Farmland's Best eggs at both Albertsons and Vons here in the last week.
Look at LinkedIn! Maybe the same will happen to ATHN. Hopefully!
11.00pm-11.30pm: Dr Elisabetta Chiarparin
Astex Pharmaceuticals, Cambridge Science Park, Milton Road, Cambridge, UK
Title: Fragment screening: an Astex perspective